AK Jain, ED, Ipca Laboratories in an interview with CNBC-TV18 said that the company has projected normal growth of around 18-20% for the whole year. But if it receives the much awaited USFDA approval then it can register much higher growth ahead.
first published: May 25, 2011 01:26 pm
A collection of the most-viewed Moneycontrol videos.
You are already a Moneycontrol Pro user.

